GoKawiil
Tech News
U.S. Customs and Border Protection announced it will suspend all personal importation of prescription medications beginning October 22, affecting Americans who order drugs from licensed Canadian pharmacies. The Canadian Pharmacy International Patients group is urging affected consumers to join its advocacy effort to preserve access to lower-cost medication.
Anthropic has quietly opened a physical biology lab in the San Francisco Bay Area, confirmed by its Head of Life Sciences Eric Kauderer-Abrams to Reuters. The lab supports both in-house experiments and outside collaborations, and is linked to but not limited to Claude Science, the drug discovery initiative Anthropic launched in June.
Researchers led by Stanford computer scientist James Zou built a system called Virtual Biotech, using up to 37,000 AI agents modeled like departments of a biotech company, overseen by a 'chief scientific officer' agent. After analyzing thousands of past clinical trials, the AI swarm flagged an immune-dampening protein as a target and, with human guidance, proposed a candidate treatment for lung cancer, detailed in a new Science paper.
Novo Nordisk has entered a partnership with Anthropic to integrate the Claude AI model into its drug-discovery operations. The collaboration is designed to build targeted tools and workflows aimed at resolving persistent bottlenecks in pharmaceutical research.
Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.
Executives from Nord Quantique and QuSecure discussed how quantum computing is moving from theoretical research toward real-world application, with heavy investment from governments and companies. They highlighted potential across drug discovery, materials science, finance and logistics, alongside the parallel risk quantum poses to current encryption standards.
Major AI companies are accelerating efforts to build superintelligent systems, pushing timelines and resources into overdrive despite unresolved safety and control questions. The push reflects competitive pressure among leading labs to be first to achieve transformative AI capabilities.
Chinese pharmaceutical companies, once known mainly for producing cheap generic medicines, are now developing original obesity and weight-loss drugs aimed at competing with Western blockbusters like Ozempic and Wegovy. Several firms are advancing candidates through clinical trials and striking licensing deals with major international drugmakers.
Douglas Yao, a self-taught chemist working outside any pharmaceutical company, says he used ChatGPT to design a new compound called PAC-3310, targeting the same receptor as the approved antipsychotic Cobenfy. He claims to have built a chemistry lab in his garage, synthesized the compound himself, and is now testing it in cell lines and mice, part of a broader effort to generate thousands of AI-designed drug candidates.
Researchers testing an AI-designed anti-aging drug reported that it lowered participants' biological age, as measured by aging clocks, in every case in the trial. The drug's development leaned on artificial intelligence tools to identify compounds likely to slow or reverse aging markers in the body.
Scientists have developed a drug delivery approach that targets specific structures within individual cells rather than simply reaching a cell as a whole. This subcellular precision aims to route therapeutic payloads to particular organelles or compartments where they can act most effectively.
Researchers are redesigning drug molecules and delivery systems so a single injection or implant can maintain therapeutic effects for weeks, months, or even years instead of requiring daily dosing. Techniques include chemical modifications that slow drug breakdown, polymer depots, and implantable devices that release medication gradually over extended periods.